The Lancet | The best science for better lives Explore the new issue by The Lancet Regional Health - Africa, an open access journal advancing clinical practice and health policy in Africa
The Lancet: Journal Homepage Explore articles from The Lancet, a world-leading medical journal founded in 1823, committed to applying scientific knowledge to improve health and advance human progress
About The Lancet medical journal The Lancet journals are both a destination for publication and a platform to advance the global impact of research The Lancet Group cares that your work is highly visible to a global network of researchers, clinicians, industry professionals, policy makers, media outlets, patients, and the wider public, and we work with you and your affiliated institutions to maximise the impact of your
The Lancet - All Issues Access all issues of The Lancet, a world-leading medical journal publishing high-quality research to advance health and science
Online First - The Lancet Explore the latest articles from The Lancet, published online ahead of print
Robert F Kennedy Jr: 1 year of failure - The Lancet In his first speech as Secretary of the US Department of Health and Human Services (HHS), Robert F Kennedy Jr laid out a plan to restore trust The COVID-19 pandemic saw public faith in Federal health and science plummet—between April, 2020, and September, 2023, the percentage of polling respondents who trusted coronavirus and vaccine information from the Centers for Disease Control and
Assessment of adverse effects attributed to statin therapy . . . - The Lancet Adverse event data from blinded randomised trials do not support causal relationships between statin therapy and most of the conditions (including cognitive impairment, depression, sleep disturbance, and peripheral neuropathy) listed in product labels as potential undesirable effects In light of these findings, such labelling and other official sources of health information should be revised
Evaluating the impact of two decades of USAID . . . - The Lancet USAID funding has significantly contributed to the reduction in adult and child mortality across low-income and middle-income countries over the past two decades Our estimates show that, unless the abrupt funding cuts announced and implemented in the first half of 2025 are reversed, a staggering number of avoidable deaths could occur by 2030
Efficacy and safety of first-line maintenance therapy with . . . - The Lancet IRF progression-free survival and overall survival were longer in the lurbinectedin plus atezolizumab group than the atezolizumab group for patients with ES-SCLC, albeit with a higher incidence of adverse events Lurbinectedin plus atezolizumab represents a novel therapeutic option for first-line maintenance treatment in this setting